- Shares of Retrophin (RTRX) are up 32% premarket on robust volume in response to the company's upward revision of its 2014 revenue guidance to $30M - 35M from $20M - 22M and 2015 revenue guidance to $60M - 70M from $36M - 41M after it acquired the marketing rights to Mission Pharmacal's Thiola (tiopronin) for the treatment of cystinuria.
- RTRX plans to file an IND within two months followed by a Phase 1 trial.
- Roth Capital rates the stock at Buy with a PT of $39.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs